索拉非尼联合顺铂对胃癌SGC7901细胞的抑制作用

目的:探讨索拉非尼联合顺铂(DDP)对胃癌SGC7901细胞的抑制作用以及可能的分子机制.方法:选取人胃癌细胞株SGC7901,用索拉非尼和DDP单药或联合作用于细胞,观察最佳抑制效果.MTT法检测索拉非尼、DDP及两药联用对胃癌SGC7901细胞的增殖抑制作用并计算半数抑制浓度(IC50);用流式细胞仪检测细胞凋亡;用Western blot观察ERK及pERK蛋白的表达.结果:MTT检测结果显示胃癌SGC7901细胞经索拉非尼、DDP单独处理以及两者联合处理后,在不同浓度均能出现细胞生长抑制作用,并且其抑制作用呈时间-剂量依赖效应.与单药组相比,联合作用组对细胞的抑制率明显增高,表现为协同作用(P＜0.05).流式细胞仪检测凋亡的结果显示,经药物处理后细胞凋亡率均较空白对照组升高,两药联合作用的凋亡率要明显高于单药组.单药组及联合用药组对SGC7901细胞ERK的表达无明显影响,但是pERK在单用索拉非尼及联合用药组的表达则降低,以联合用药组尤甚.结论:索拉非尼联合顺铂对胃癌SGC7901细胞有增殖抑制及促凋亡的作用,两药联合表现为协同作用,其机制可能与细胞增殖通路Raf/MEK/ERK的机制有关.     

阿霉素联合顺铂诱导宫颈癌细胞凋亡实验研究

目的:研究化疗药物阿霉素(ADM)联合顺铂(DDP)对宫颈癌CaSki细胞株的增殖及凋亡的影响,并探讨其可能的相互作用机制。方法:应用MTT比色法检测不同浓度阿霉素、顺铂单独和联合应用对宫颈癌CaSki细胞的增殖抑制作用;同时RT-PCR法在mRNA水平上检测Bcl-2和TNF-α基因表达量的变化。结果:两种药物单独应用均可抑制CaSki细胞的增殖,联合用药(<12μg/mL)时具有协同抑制作用并与各药物单一应用比较具有显著性差异(P<0.05);阿霉素、顺铂作用CaSki细胞后能上调TNF-α基因和下调Bcl-2基因的表达。结论:宫颈癌CaSki细胞在化疗药物阿霉素和顺铂两药联合作用下通过诱导TNF-α和Bcl-2 mRNA表达量的变化发挥协同抑制作用,同时TNF-α的高表达增强了化疗药物阿霉素和顺铂诱导肿瘤细胞凋亡的敏感性,其机制主要与凋亡诱导效应有关。     

胃癌SGC7901 表柔比星耐药细胞亚系的建立与耐药机制研究

目的:建立人胃癌SGC7901表柔比星耐药细胞系,探讨其对表柔比星的耐药机制。方法:采用逐步增加表柔比星浓度,间歇作用体外诱导法,建立人胃癌SGC7901表柔比星耐药细胞亚系SGC7901/EPI。用MTT法测定药物敏感性;流式细胞仪检测其药物排除能力和凋亡抵抗能力等生物学指标的改变,western blot检测相关蛋白的表达。结果:经过12个月建成人胃癌SGC7901表柔比星耐药细胞系SGC7901/EPI,其对表柔比星明显耐药,且对其他多种抗癌药具有不同程度的交叉耐药性,阿霉素蓄积潴留实验显示SGC7901/EPI的阿霉素含量明显低于亲本细胞,Western blot显示MRP1的表达上调;SGC7901/EPI凋亡抵抗能力明显上升,Bcl-2表达比亲本细胞增高,而Bax的表达下调。结论:SGC7901/EPI细胞具有多药耐药表型,其可能通过MRP1的上调增加药物排出和上调Bcl-2/Bax的比值促进凋亡抵抗等机制产生耐药。该胃癌多药耐药细胞亚系为进一步研究胃癌耐药机制及逆转方法奠定基础。     

miR-17-92对急性白血病L1210/DDP细胞多药耐药性影响研究

目的:研究miR-17-92在白血病L1210/DDP细胞多药耐药形成中的作用.方法:首先构建L1210/DDP耐药细胞系,运用real-time PCR方法检测miR-17-92在L1210/DDP细胞与L1210细胞中的表达差异.利用脂质体Lipofectamine 2000将miR-17-92抑制物(miR-17-92sponge)及阴性对照(sponge vector)转染L1210/DDP细胞,构建miR-17-92表达下调的L1210/DDP细胞系.用MTS法检测转染后耐药细胞对顺铂和阿霉素体外药物敏感性.结果:miRNA-17-92在L1210/DDP耐药细胞系中高表达,上调倍数为(1.61±0.01)倍.体外药物敏感性实验表明,转染miR-17-92抑制物的实验组对顺铂和阿霉素的IC50分别为(3.29±0.51)、(1.35±0.13)g/ml,而转染阴性对照组对上述药物的IC50分别为(6.73± 0.82)、(2.66±0.42)g/ml,在耐药株中抑制miR-17-92在L1210/DDP细胞中的表达,显著增加细胞对顺铂和阿霉素的敏感性.结论:miR-17-92在白血病耐顺铂L1210/DDP细胞中高表达.抑制miR-17-92的表达可增加白血病L1210/DDP细胞对顺铂和阿霉素化疗药物的敏感性,部分逆转耐药.     

消化道癌原代培养体外药敏试验的研究

目的 研究肠癌、胃癌、肝癌细胞在8种不同抗癌药物作用下的细胞抑制率,以筛选出敏感的化疗药物.方法 采用四甲基偶氮唑蓝着色法（MTT）,对97例消化道癌（43例肠癌、33例胃癌、21例肝癌）新鲜瘤组织进行原代细胞培养,同时进行顺铂（DDP）、丝裂霉素（MMC）、卡铂（CBP）、5-氟尿嘧啶（5-FU）、表阿霉素（EADM）、长春新碱（VCR）、羟基喜树碱（OPT）和环磷酰胺（CTX）8种常用化疗药物敏感检测,并对其结果作比较.结果 在肠癌中高度敏感率大于50%药物依次为MMC、5-FU、DDP、CBP.总敏感率大于50%的药物依次为DDP、MMC、5-FU、CBP.在胃癌中高度敏感率大于50%的药物依次为DDP、CBP.总敏感率大于50%的药物依次为DDP、CBP、MMC、5-FU、CTX、VCR.其中胃癌对CTX、VCR的敏感率明显高于肠癌细胞（P＜0.05）.肝癌细胞中高度敏感率＞50%的药物为零,而总敏感率＞50%的药物依次排序为MMC、EADM、CBP.结论 消化道肿瘤细胞对化疗药物的选择虽有一定共性,但同种肿瘤的不同个体对同种化疗药物的敏感性差异却存有显著性.体外检测消化道肿瘤对化疗药物的敏感性可为临床化疗提供指导.     

Bmi-1稳定干扰增加乳腺癌细胞对化疗药物的敏感性

目的:观察Bmi-1稳定干扰后对乳腺癌细胞药敏性的影响.方法:构建Bmi-1 shRNA逆转录病毒表达载体,并用该逆转录病毒感染人乳腺癌细胞,建立Bmi-1稳定干扰的乳腺癌细胞株.采用不同浓度的化疗药物5-氟尿嘧啶和顺铂处理上述细胞,MTT法观察乳腺癌细胞的生长抑制率.结果:免疫印迹检测结果表明Bmi-1稳定干扰的乳腺癌细胞株成功建立.MTT检测显示Bmi-1稳定干扰的乳腺癌细胞(MDA-MB-435S-Bmi-1/RNAi)增殖抑制率显著高于对照细胞(MDA-MB-435S-vector)(P<0.05),并且呈浓度依赖性.其中在MDA-MB-435S-vector中5-氟尿嘧啶和顺铂的IC50值分别为1.7233 mg/L和2.9065 mg/L,而在MDA-MB-435S Bmi-1/RNAi稳定细胞株5-氟尿嘧啶和顺铂中的IC50值分别为0.9733 mg/L和1.8563mg/L(P<0.05).结论:Bmi-1在乳腺癌细胞对化疗药物敏感性中发挥重要作用,Bmi-1干扰能增加乳腺癌细胞对化疗药物的敏感性.     

温热抑制人胃癌SGC7901细胞增殖、迁移

目的探讨温热对人胃癌SGC790l细胞增殖、迁移的影响。方法对照组常温(37℃)下培养人胃癌SGC790l细胞,实验组43℃水浴加热0.5h、1h、2h、3h后培养24h,采用倒置显微镜观察胃癌细胞的形态结构变化;Hoechst-33258荧光染色观察细胞核的变化;四甲基偶氮唑盐比色法(MTT)检测细胞增殖抑制;细胞划痕愈合实验观察温热对胃癌细胞的运动迁移能力的影响;体外细胞侵袭实验(Transwell实验)观察温热对胃癌细胞侵袭能力的影响。结果温热后细胞明显皱缩、变圆及细胞漂浮,3h大部分细胞漂浮;荧光染色显示温热后部分细胞核内出现浓染致密的颗粒块状荧光,胞核固缩、染色质高度凝聚和碎裂;MTT实验提示温热可明显抑制SGC790l细胞生长;细胞划痕实验发现SGC790l细胞温热1h、2 h后细胞迁移距离均明显小于对照组,温热3h后细胞基本未发生迁移;Transwell实验提示SGC790l细胞温热后细胞侵袭能力明显下降。结论温热对胃癌SGC790l细胞具有明显的杀伤作用,温热可明显抑制胃癌SGC790l细胞增殖和侵袭迁移能力。     

化疗药物对细胞因子诱导的杀伤细胞(CIK)的影响

探讨化疗药物及地塞米松对CIK细胞增殖活性及淋巴细胞亚群的影响。分别选取不同浓度顺铂、氟尿嘧啶、紫杉醇和地塞米松与不同诱导天数的CIK细胞共培养,在加入或不加入IL-2的情况下,采用MTT法检测各种药物对CIK细胞增殖活性的影响,流式细胞术检测CIK细胞中各亚群的比例。顺铂、氟尿嘧啶、紫杉醇及地塞米松均在一定程度上抑制CIK细胞的增殖活性,其中顺铂和紫杉醇表现出明显的剂量依赖性(P0.05);IL-2可对CIK细胞产生保护作用,在一定程度上降低化疗药物对CIK细胞的抑制作用(P0.05)。顺铂主要降低CD3+CD56+亚群比例(P0.05),对CD3+CD4+、CD3+CD8+亚群比例无显著影响(P0.05)。     

斑马鱼胚胎和肿瘤细胞评价细胞毒药物活性比较研究*

目的:比较斑马鱼胚胎和肿瘤细胞作为药物筛选模型的优缺点.方法:采用MTT法检测顺铂、紫杉醇、阿霉素、5-氟尿嘧啶四种药物对HL-60和Hela细胞的增殖影响;同时,观察药物对斑马鱼胚胎发育的影响.结果:阿霉素、顺铂及紫杉醇作用于HL-60及Hela细胞的IC50均显著高于作用于斑马鱼胚胎的LD50;而5-FU作用于肿瘤细胞和斑马鱼胚胎的结果与其它药物相反;四种抗肿瘤药物对斑马鱼胚胎的生长发育均有致畸作用.结论:斑马鱼胚胎作为细胞毒类药物筛选模型,对于抗微管类药物较为敏感,但对于抗代谢药敏感性较肿瘤细胞差.     

24例维吾尔族宫颈癌新辅助化疗临床疗效分析

目的:研究5-氟尿嘧啶、丝裂霉素加顺铂在局部晚期宫颈癌术前新辅助化疗中的作用.方法:应用5.氟尿嘧啶、丝裂霉素加铂类经股动脉插管,超选择性选择子宫动脉对局部晚期维族宫颈癌术前进行灌注化疗后栓塞,观察24例患者化疗前后局部肿瘤体积变化、手术切除率、盆腔淋巴结转移、脉管癌栓、病灶局部化疗反应.结果:作为术前新辅助化疗,肿瘤体积缩小总有效率87.5%,CR16.66%,手术切除率100%.结论:5-氟尿嘧啶、丝裂霉素加铂类方案联合化疗在局部晚期宫颈癌术前新辅助化疗方面疗效明显.     

姜半夏乙醇提取物对人胃癌SGC7901细胞增殖和凋亡的影响

目的：观察姜半夏乙醇提取物对人胃癌SGC7901细胞增殖和凋亡的影响。方法：不同浓度姜半夏乙醇提取物（终浓度为1mg／ml,0．5mg／ml,0．25mg／ml,0．125mg／ml）处理SGC7901细胞后,倒置相差显微镜下观察细胞的形态学变化;通过甲基噻唑基四唑法检测细胞增殖状况、描绘生长曲线,使用紫外分光光度法观察药物干预后细胞ATP酶活力;AnnexinV．异硫氰酸荧光素（fluorescein isothiocyanate,FITC）／碘化丙啶（propidium iodide,PI）双标记法流式细胞术检测姜半夏乙醇提取物对SGC7901细胞诱导凋亡的情况。结果：不同浓度姜半夏乙醇提取物均能不同程度地抑制人胃癌SGC7901细胞的增殖;在姜半夏乙醇提取物诱导细胞后细胞发生了边缘毛刺、体积缩小等形态学变化,同时可见细胞折光度和贴壁能力下降;Annexin V-F／TC／PI双标记法检测显示姜半夏乙醇提取物可诱导细胞发生凋亡;细胞总ATP酶活力在药物干预72小时后出现明显下降;并且随着药物浓度增加细胞凋亡率、细胞形态异常改变以及ATP酶活力抑制作用均呈上升趋势。结论：姜半夏乙醇提取物可抑制人胃癌SGC7901细胞的增殖,促进其凋亡,抑制细胞ATP酶活力。     

The Inhibitory Effect of Pseudolaric Acid B on Gastric Cancer and Multidrug Resistance via Cox-2/PKC-α/P-gp Pathway

Aim

To investigate the inhibitory effect of pseudolaric acid B on subcutaneous xenografts of human gastric adenocarcinoma and the underlying molecular mechanisms involved in its multidrug resistance.

Methods

Human gastric adenocarcinoma SGC7901 cells and drug-resistant SGC7901/ADR cells were injected into nude mice to establish a subcutaneous xenograft model. The effects of pseudolaric acid B with or without adriamycin treatment were compared by determining the tumor size and weight. Cyclo-oxygenase-2, protein kinaseC-α and P-glycoprotein expression levels were determined by immunohistochemistry and western blot.

Results

Pseudolaric acid B significantly suppressed the tumor growth induced by SGC7901 cells and SGC7901/ADR cells. The combination of pseudolaric acid B and the traditional chemotherapy drug adriamycin exhibited more potent inhibitory effects on the growth of gastric cancer in vivo than treatment with either pseudolaric acid B or adriamycin alone. Protein expression levels of cyclo-oxygenase-2, protein kinaseC-α and P-glycoprotein were inhibited by pseudolaric acid B alone or in combination with adriamycin in SGC7901/ADR cell xenografts.

Conclusion

Pseudolaric acid B has a significant inhibitory effect and an additive inhibitory effect in combination with adriamycin on the growth of gastric cancer in vivo, which reverses the multidrug resistance of gastric neoplasm to chemotherapy drugs by downregulating the Cox-2/PKC-α/P-gp/mdr1 signaling pathway.     

Detection of potassium currents and regulation of multidrug resistance by potassium channels in human gastric cancer cells

The present study aimed to investigate the potassium currents and further explore the role of potassium channels in drug response of gastric cancer cells. By patch-clamp technique, potassium currents of human gastric cancer cell SGC7901 were recorded in the mode of voltage clamp. Both 4-aminopyridine (4-AP) and tetraethylammonium (TEA) could almost completely block this current. The chemotherapeutic drugs, adriamycin or 5-fluorouracil could significantly increase the K(+) current density on SGC7901 cells in a dose-dependent manner. 4-AP or TEA was found to restrain adriamycin-induced apoptosis and enhance multidrug-resistant phenotype of SGC7901 cells. Up-regulation of Kv1.5, which has been found widely expressed in gastric cancer cells including SGC7901, increased the K(+) current density and sensitivity of SGC7901 cells to multiple chemotherapeutic drugs, whereas down-regulation of Kv1.5 enhanced the drug-resistant phenotype of SGC7901 cells. In conclusion, potassium channels may exert regulatory effects on multidrug resistance by regulating drug-induced apoptosis in gastric cancer cells.     

Activation of LXRβ inhibits proliferation,promotes apoptosis,and increases chemosensitivity of gastric cancer cells by upregulating the expression of ATF4

Recently, great advances have been achieved in both surgery and chemotherapy for the treatment of gastric cancer, but there is still poor prognosis for this disease. The aim of this study is to investigate the role of liver X receptor β (LXRβ) in chemosensitivity of gastric cancer SGC7901 cells. From 171 patients with gastric cancer, the gastric cancer and paracancerous tissues were selected to measure the expression of LXRβ and ATF4. Gastric cancer cell lines were cultured and screened to figure out the proliferation and apoptosis of gastric cancer SGC7901 cells with the treatment of LXRβ agonist (GW3965), ATF4 short hairpin RNA (shRNA), and chemotherapy drug paclitaxel. The expression of apoptosis-related gene cleaved caspase-3 was detected by Western blot analysis. First, we found that the expressions of LXRβ and ATF4 in gastric cancer tissues and cells were significantly lower than those in their paracancerous tissues and gastric mucosal epithelial cells. In addition, activation of LXRβ and paclitaxel treatment suppressed proliferation of SGC7901 cells, and the expression of ATF4 was upregulated in a concentration-dependent manner. Furthermore, shRNA significantly inhibited the expression of ATF4 and blocked the chemosensitivity of SGC7901 cells to LXRβ activation. Our study demonstrates that the expression of LXRβ was low in gastric cancer. In addition, activation of LXRβ may inhibit the proliferation of gastric cancer cells, promote apoptosis, and increase chemosensitivity by upregulating the expression of ATF4.     

CXXC finger protein 4 inhibits the CDK18‐ERK1/2 axis to suppress the immune escape of gastric cancer cells with involvement of ELK1/MIR100HG pathway

Gastric cancer, is the fourth most common tumour type yet, ranks second in terms of the prevalence of cancer‐related deaths worldwide. CXXC finger protein 4 (CXXC4) has been considered as a novel cancer suppressive factor, including gastric cancer. This study attempted to investigate the possible function of CXXC4 in gastric cancer and the underlying mechanism. The binding of the ETS domain‐containing protein‐1 (ELK1) to the long non‐coding RNA MIR100HG promoter region was identified. Then, their expression patterns in gastric cancer tissues and cells (SGC7901) were detected. A CCK‐8 assay was used to detect SGC7901 cell proliferation. Subsequently, SGC7901 cells were co‐cultured with CD3+ T cells, followed by measurement of CD3+ T cell proliferation, magnitude of IFN‐γ+ T cell population and IFN‐γ secretion. A nude mouse model was subsequently developed for in vivo validation of the in vitro results. Low CXXC4 expression was found in SGC7901 cells. Nuclear entry of ELK1 can be inhibited by suppression of the extent of ELK1 phosphorylation. Furthermore, ELK1 is able to bind the MIR100HG promoter. Overexpression of CXXC4 resulted in weakened binding of ELK1 to the MIR100HG promoter, leading to a reduced proliferative potential of SGC7901 cells, and an increase in IFN‐γ secretion from CD3+ T cells. Moreover, in vivo experiments revealed that CXXC4 inhibited immune escape of gastric cancer cells through the ERK1/2 axis. Inhibition of the CXXC4/ELK1/MIR100HG pathway suppressed the immune escape of gastric cancer cells, highlighting a possible therapeutic target for the treatment of gastric cancer.     

Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis

Ribosomal proteins (RP) S13 and RPL23 were previously identified as two upregulated genes in a multidrug-resistant gastric cancer cell line SGC7901/VCR compared to its parental cell SGC7901 by differential display PCR. The aim of this study was to explore the roles of RPS13 and RPL23 in multidrug resistance (MDR) in gastric cancer cells. RPS13 and RPL23 were genetically overexpressed in SGC7901 cells, respectively. Either RPS13 or RPL23 enhanced resistance of SGC7901 cells to vincristine, adriamycin, and 5-fludrouracil. RPL23 also enhanced resistance of SGC7901 cells to cisplatin. Overexpression of either RPS13 or RPL23 did not alter the population doubling time, [³H]leucine incorporation, and intracellular adriamycin accumulation of SGC7901 cells. However, either RPS13 or RPL23 could protect SGC7901 cells from undergoing vincristine-induced apoptosis. Western blot analysis revealed that both RPS13 and RPL23 significantly increased the expression level of Bcl-2 and Bcl-2/Bax ratio in SGC7901 cells. In addition, overexpression of RPL23 enhanced glutathione S-transferase (GST) activity and intracellular glutathione content in SGC7901 cells. Together, this work demonstrates that either RPS13 or RPL23 can promote MDR in gastric cancer cells by suppressing drug-induced apoptosis, and that RPL23 may also promote MDR in gastric cancer cells through regulation of glutathione S-transferase-mediated drug-detoxifying system.     

Sunitinib Reverse Multidrug Resistance in Gastric Cancer Cells by Modulating Stat3 and Inhibiting P-gp Function

Sunitinib, a small-molecule multi-targeted tyrosine kinase inhibitor, has been applied in phase II clinical trial as second-line treatment for advanced gastric cancer. In this study, we determined the effect of Sunitinib on the multidrug resistance in gastric cancer cells selected by vincristine. Our results showed that Sunitinib significantly enhanced the cytotoxicity of adriamycin, vincristine, etoposide, 5-Fluorouracil, and cisplatin in multidrug-resistant gastric cancer cells (SGC7901/VCR). Sunitinib significantly increased the intracellular accumulation and retention of rhodamine 123 in the SGC7901/VCR cells. However, Sunitinib, at a concentration that reverses MDR, had no significant effect on P-gp protein or mRNA expression levels. In addition, the present study revealed that Sunitinib inhibited Stat3 and down-regulated Bcl-2 in SGC7901/VCR cells, which might also contribute to the reversal of MDR. In conclusion, Sunitinib reverses multidrug resistance in gastric cancer cells by inhibiting P-gp transporter function and modulating Stat3 and Bcl-2. Further study with Sunitinib may be helpful for developing combination therapeutic strategy or circumventing gastric cancer MDR to other conventional anti-cancer drugs.     

Enhancement of Metastatic and Invasive Capacity of Gastric Cancer Cells by Transforming Growth Factor-β1

Transforming growth factor-β (TGF-β),a multifunctional cytokine,exerts contradictory rolesin different kinds of cells.A number of studies have revealed its involvement in the progression of many typesof tumors.To investigate the effect of TGF-β on gastric carcinoma,SGC7901,BGC823 and MKN28 (aTGF-β-resistant cell line) adenocarcinoma clones were used.After pretreatment in serum-free medium withor without 10 ng/ml TGF-β1,their experimental metastatic potential,chemotaxis,and invasive and adhesiveability were measured.Furthermore,zymography for gelatinase was processed.Liver colonies were alsomeasured 4 weeks after inoculation of SGC7901,BGC823 and MKN28 in Balb/c nude mice,and an increasein the number of surface liver metastases was seen in SGC7901 (from 11.0±3.0 to 53.3±3.3) and BGC823(from 9.3±2.5 to 60.0±2.8) groups,whereas there was no difference between MKN28 groups (from 35.2±3.8 to 38.5±2.7).In vitro experiments showed that TGF-β1 increased the adhesion capacity of SGC7901and BGC823 cells to immobilized reconstituted basement membrane/fibronectin matrices and promoted theirpenetration through reconstituted basement membrane barriers.Zymography demonstrated that enhancedinvasive potential was partly due to the increased type Ⅳ collagenolytic (gelatinolytic) activity,but there wasno difference in type Ⅳ collagenolytic activity and other biological behaviors between MKN28 groups.Theseresults suggested that TGF-β1 might modulate the metastatic potential of gastric cancer cells by promotingtheir ability to break down and penetrate basement membrane barriers and their adhesive and motile activities.We speculated that TGF-β1 might act as a progression-enhancing factor in gastric cancer.Therefore blockageof TGF-β or TGF-β signaling might prevent gastric cancer cells from invading and metastasizing.     

Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR

In order to elucidate the mechanisms of multidrug resistance (MDR) of vincristine-resistant human gastric carcinoma cell line SGC7901/VCR, 2-DE was used to separate the total proteins of SGC7901/VCR and its parental cell line SGC7901. PDQuest software was applied to analyze 2-DE images, and the differential protein spots were identified by both MALDI-TOF-MS and ESI-Q-TOF-MS. Then the differential expressional levels of partially identified proteins were determined by Western blot analysis and real-time RT-PCR. Furthermore, the association of heat shock protein (HSP27), one of the highly expressed proteins in sgc7901/vcr, with MDR was analyzed using antisense inhibition of HSP27. In this study, the well-resolved, reproducible 2-DE patterns of SGC7901/VCR and SGC7901 were established, and yielded about 1100 protein-spots each. All the 24 differential proteins between the two cell lines were identified, and the differential expression levels of the partial proteins were confirmed. The suppression of HSP27 expression by HSP27 antisense oligonucleotides could enhance vincristine chemosensitivity in sgc7901/vcr and induce the cells to exhibit apoptotic morphological features after vincristine treatment. The differentially expressed proteins could be divided into six groups based on their functions: calcium-binding proteins, chaperones, proteins involved in drug detoxification or repair of DNA damage, metabolic enzymes, proteins related to cellular structure, and proteins relative to signal transduction, some of which may contribute to MDR of human gastric carcinoma cell line SGC7901/VCR. These data will be valuable for further study of the mechanisms of MDR in human gastric cancer.